Cargando…
Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer
Nearly 45% of colorectal cancer (CRC) patients harbor a mutation in their KRAS gene for which, despite many years of research, there are still no targeted therapies available. Protein Arginine Methyltransferase 5 (PRMT5) is a transcription regulator for multiple cellular processes that is currently...
Autores principales: | Shifteh, David, Sapir, Tzuriel, Pahmer, Moshe, Haimowitz, Adam, Goel, Sanjay, Maitra, Radhashree |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465151/ https://www.ncbi.nlm.nih.gov/pubmed/32731506 http://dx.doi.org/10.3390/cancers12082091 |
Ejemplares similares
-
Therapeutic Targets of KRAS in Colorectal Cancer
por: Rahman, Shafia, et al.
Publicado: (2021) -
Noncoding RNA Profile in Reovirus Treated KRAS-Mutated Colorectal Cancer Patients
por: Saperstein, Rafael, et al.
Publicado: (2023) -
Transcriptome Signature of Immune Cells Post Reovirus Treatment in KRAS Mutated Colorectal Cancer
por: Fogel, Elisha J, et al.
Publicado: (2021) -
Toll-like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer
por: Maitra, Radhashree, et al.
Publicado: (2017) -
Development and Characterization of a Genetic Mouse Model of KRAS Mutated Colorectal Cancer
por: Maitra, Radhashree, et al.
Publicado: (2019)